LOGIN  |  REGISTER
Astria Therapeutics

Certara to Participate in the William Blair Growth Stock Conference and Jefferies Virtual Healthcare Conference

May 20, 2021 | Last Trade: US$11.88 0.26 2.24

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that William Feehery, Chief Executive Officer, and Andrew Schemick, Chief Financial Officer, will participate in the following virtual investor conferences:

  • William Blair's 41st Annual Growth Stock Conference
    Fireside Chat on Tuesday, June 1st at 11:40 a.m. ET
  • Jefferies Virtual Healthcare Conference
    Fireside Chat on Friday, June 4th at 10:00 a.m. ET

Live webcasts will be available on Certara’s investor relations website at https://ir.certara.com and will be available for replay for 90 days thereafter.

About Certara

Certara accelerates medicines using biosimulation software and technology to transform traditional drug discovery and development. Its clients include more than 1,650 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 61 countries.

Investor Relations Contact:
David Deuchler
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Ariane Lovell
Finn Partners
This email address is being protected from spambots. You need JavaScript enabled to view it. 


Astria Therapeutics

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page